ADTX_OUT_1 [2025-04-02 14:25:53 -0400] 3518 Bytes | 977 tokens | Cum: 977 tkns (12.21% of 8k)
==========================================================================

Alright, let’s light it up, because it's 2:25:53 PM on Wed Apr 02, 2025 -0400, and I'm charging into Aditxt (ADTX), popping from 4.52 to 5.3056. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Aditxt (ADTX)
IPO: 2020-06-30 (4 Years Ago)
Market Cap: $4,660,581
Shares Outstanding: 1,030,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.

Here's the first list of news for Aditxt:

C1 - Today 08:17AM - Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
C2 - 08:15AM - Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
C3 - Mar-28-25 08:15AM - Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
C4 - Mar-24-25 08:30AM - Evofem Reports Fourth Consecutive Year of Net Sales Growth
C5 - Mar-24-25 08:30AM 08:15AM - Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
C6 - Mar-18-25 07:22AM - Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
C7 - Mar-17-25 08:15AM - Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025
C8 - Mar-12-25 04:15PM - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Prior AI Reports for ADTX:
1. 2025-03-20 – Score: 20 – Target: 14.0000 – Highs: 12.9199 / 10.1558 / 9.25
aditxts-high-volatility-and-negative-performance-indicate-risk
2. 2025-03-19 – Score: 10 – Target: 10.2200 – Highs: 12.3000 / 12.9199 / 10.16
companys-dire-financial-state-raises-serious-concerns

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Aditxt (ADTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ADTX_OUT_3 [2025-04-02 14:25:57 -0400] 587 Bytes | 171 tokens | Cum: 1150 tkns (14.37% of 8k)
==========================================================================

Showing C3 (chunk 1 of 1): C3:
**Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection**
Date: Mar-28-25 08:15AM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20250328225845/en

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20250328225845/en

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADTX_OUT_5 [2025-04-02 14:25:57 -0400] 1039 Bytes | 321 tokens | Cum: 1543 tkns (19.29% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T12:34:07Z - Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on Apr...
A2 - 2025-04-02T12:17:00Z - Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on Apr...
A3 - 2025-04-02T12:34:41Z - Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on Apr...
A4 - 2025-04-02T12:18:11Z - Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on Apr...
A5 - 2025-04-02T12:26:12Z - Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on Apr...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ADTX_OUT_7 [2025-04-02 14:26:01 -0400] 1098 Bytes | 337 tokens | Cum: 1882 tkns (23.52% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025**Date: 2025-04-02Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/02/tmt-newswire/globenewswire/appili-president-and-ceo-don-cilla-to-join-aditxt-ceo-amro-albanna-for-aditxt-weekly-update-on-april-4-2025/2085133Event exploring the escalating threat of emerging infectious diseases

Discussion covering going-private transaction with Aditxt, strategic growth partner

HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, In

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADTX_OUT_9 [2025-04-02 14:26:02 -0400] 990 Bytes | 298 tokens | Cum: 2270 tkns (28.38% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-11-06T22:55:00Z - Appili Therapeutics Announces Results of Special Meeting of Shareholders
B2 - 2024-10-10T19:40:00Z - Appili Therapeutics – Press Release Correction
B3 - 2024-04-02T17:23:42Z - Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B4 - 2024-01-02T18:35:24Z - Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B5 - 2024-01-02T13:07:57Z - Why LumiraDx Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
B6 - 2023-12-29T18:03:42Z - Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ADTX_OUT_11 [2025-04-02 14:26:08 -0400] 1102 Bytes | 315 tokens | Cum: 2587 tkns (32.34% of 8k)
==========================================================================

Showing B3 (chunk 1 of 3): B3:
**Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/04/38053729/why-stryve-foods-shares-are-trading-lower-by-around-25-here-are-other-stocks-moving-in-tuesdays-midShares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.
Stryve Foods posted adjusted loss of $1.90 per share, versus market estimates for a loss of $1.96 per share. The company’s sales came in at $2.887 million versus expectations of $5.009 million, according to data from Benzinga Pro.
Stryve Foods shares dipped 25.2% to $1.0965 on Tuesday.
Here are some other stocks moving in today's mid-day session.
Gainers

VivoPower International PLC (NASDAQ: VVPR) shares surged 315% to $6.10 after the company's Tembo subsidiary

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADTX_OUT_13 [2025-04-02 14:26:08 -0400] 1088 Bytes | 295 tokens | Cum: 3002 tkns (37.52% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and other financ...

S2 - 2025-03-31 8-K Item 7.01 Regulation FD Disclosure.

On March 28, 2025, Aditxt, Inc. (the Company ) hosted a corporate update featuring Amro Albanna, the Chf Exec Off of the Company, Dr. Shahrokh Shabahang, the Chf Innovation Off of the Company, Chris Mitton, the President of P...

S3 - 2025-03-24 8-K Item 7.01 Regulation FD Disclosure.

On March 21, 2025, Aditxt, Inc. (the Company ) hosted a corporate update featuring Amro Albanna, the Chf Exec Off of the Company, and Saundra Pelletier, the Chf Exec Off of Evofem Biosciences, Inc., an acquisition target...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ADTX_OUT_15 [2025-04-02 14:26:09 -0400] 1098 Bytes | 226 tokens | Cum: 3230 tkns (40.38% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and other financial information included elsewhere in this report. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See Cautionary Note Regarding Forward-Looking Statements.

Overview and Mission

We believe the world needsand deservesa new approach to innovating that harnesses the power of large groups of stakeholders who work together to ensure that the most promising innovations make it into the hands of people who

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADTX_OUT_17 [2025-04-02 14:26:21 -0400] 4206 Bytes | 1183 tokens | Cum: 4415 tkns (55.19% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-------------------------+
| Volume: 132,673 | Perf Month: -58.15% | Option/Short: No / Yes | Sales Y/Y TTM: -79.23% |
+--------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 2.97M | Perf Quarter: -89.32% | Short Float: 2.85% | ROE: -276.39% |
+--------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 0.06 | Index: - | Short Ratio: 0.01 | ROI: -433.63% |
+--------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 33.54 | Market Cap: 6.04M | Short Interest: 0.03M | Sales Surprise: 120.59% |
+--------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 2.88 | Shs Outstand: 1.03M | Beta: 1.36 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA20: -39.03% | Shs Float: 1.03M | Sales Q/Q: -96.09% | P/E: - |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA50: -70.05% | Inst Own: 0.03% | Sales past 5Y: - | Earnings: - |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA200: -99.87% | Insider Own: 0.00% | Employees: 26 | |
+--------------------+-----------------------+------------------------+-------------------------+
| Perf Week: -23.94% | Insider Trans: - | Debt/Eq: 0.78 | |
+--------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 506441, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -84099687.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 5.36
Average Volume: 7152101.36
30-Day High: 15
30-Day Low: 4.37

[Detailed Financials: Q1 2024]
- Total Assets: $27,975,521.0
- Total Liabilities: $18,193,761.0
- Total Equity: $9,781,760.0
- Current Assets: $1,595,367.0
- Current Liabilities: $17,302,014.0

[Income Statement: Q1 2024]
- Revenue: $79,680.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -9.14

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $0

[Detailed Financials: FY 2023]
- Total Assets: $44,578,327.0
- Total Liabilities: $28,531,558.0
- Total Equity: $16,046,769.0
- Current Assets: $6,912,948.0
- Current Liabilities: $25,889,814.0

[Income Statement: FY 2023]
- Revenue: $645,176.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -108.15

[Cash Flow Statement: FY 2023]
- Net Cash Flow: $-2,671,538.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ADTX_OUT_19 [2025-04-02 14:26:25 -0400] 676 Bytes | 167 tokens | Cum: 4862 tkns (60.77% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ADTX_IN_21 [2025-04-02 14:26:25 -0400] 126 Bytes | 29 tokens | Cum: 4969 tkns (62.11% of 8k)
==========================================================================

====================================
[2025-04-02 14:26:25] # Analysis Completed
Elapsed Time: 32.55 seconds